Edison Investment Research - VolitionRX (VNRX) QuickView: Detecting cancer one drop of blood at a time

Report

Edison Investment Research

QuickView: Detecting cancer one drop of blood at a time

VolitionRx develops cost-effective blood-based cancer diagnostics based on its proprietary NuQ technology, which detects the level and structure of nucleosomes in the blood using one drop of blood serum. It is currently focused on colorectal cancer (CRC), a very large opportunity with at least 125 million people aged 50-75 not currently being screened with colonoscopies or fecal-based tests for CRC in the US and EU. Data so far have suggested 84% sensitivity and 78% specificity in detecting CRC.

15/05/2015 2 EN

Underlying

VolitionRX

See profile

US9286611077 NYSE MKT United States

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Other Reports on these Companies

Edison Investment Research

VolitionRx - Snaring sepsis, with early NETs detection

VolitionRx continues to make headway in growing a body of clinical evidence to build Nu.Q® NETs as a potential breakthrough tool in sepsis. These efforts, coupled with its CE mark in Europe, are a strong foundation in rapid and simplified sepsis detection that seeks to address the limitations and complexities of the current standard of care. Sepsis (immune-system triggered organ dysfunction) has a worrisome prevalence, affecting c 50 million per year with a mortality rate of c 20–25%, exceeding the combination of many leading cancers. Further, every hour of delayed treatment increases the chan...

February 8, 2024 February 8, 2024 1 EN

Edison Investment Research

VolitionRx - Vetting the pet health opportunity

While pets are increasingly being ‘humanized’, their healthcare has lagged advancements seen on the human side. With the COVID-19 pandemic accelerating the trend of pet ownership, demand for improved care in a market with limited alternatives has triggered the need for newer-generation pet diagnostics. VolitionRx, a diagnostics company focused on sepsis and cancer detection, has pioneered a low-cost, quick-turnaround, cancer screening and monitoring tool for companion animals (Nu.Q Vet), an adaption of its core nucleosome quantification (Nu.Q) platform on the human side. With supply and distri...

January 17, 2023 January 17, 2023 1 EN

Edison Investment Research

VolitionRX - Unravelling the web of NETs in sepsis

VolitionRx is a clinical diagnostics company with a different perspective on immunoassay technology for the detection and monitoring of severe diseases in both humans and companion animals. Unlike sequential organ failure assessment (SOFA), which requires multiple physiological measurements, VolitionRx’s proprietary Nu.Q neutrophil extracellular traps (NETs) immunoassay technology takes a more direct route in a largely stale and fragmented market. This ability to rapidly diagnose and monitor patients supports numerous clinical use cases across specialties and most immediately addresses sepsis,...

August 15, 2022 August 15, 2022 1 EN

International Public Partnerships - Consistently and responsibly delivering

International Public Partnerships’ (INPP’s) FY23 results show that it continues to deliver consistent and predictable returns for investors, while delivering environmental and social benefits for the individuals and communities that are served by its assets. Despite this strong performance and a substantial need for private infrastructure funding, the macroeconomic environment has weighed on INPP’s share price, in common with the wider sector. Regardless, attractive returns are available from the existing portfolio with opportunities for further enhancement.

3h / 55m 3h / 55m 1 EN

Kate Heseltine

Kate Heseltine

Portobello SpA - Focus back on the operations

Portobello’s FY23 results demonstrate the primary effects of the out-of-court settlement with respect to VAT and direct taxes (a higher year-end net debt position) and the secondary effects, such as disruption to its trading activities due to management’s focus on cash generation and the company’s inability to trade as previously expected. Following the period end, two capital raises totalling €12.6m, including €3.8m by three of the executive management team, from a maximum mandated amount of €20m, have improved the company’s financial position. The requirement to improve the balance sheet fur...

4h / 39m 4h / 39m 1 EN

Kate Heseltine

Kate Heseltine

Intralot - Focus on business development in FY24

Intralot enjoyed good underlying trends in performance in FY23 with encouraging trends in its main countries of focus and further progress on profitability. The much-improved balance sheet and extension of debt maturities mean management can focus on the significant business development opportunities available in FY24 and beyond. The share price looks attractive in the absence of potential new contract wins, which could be materially enhancing to the valuation.

9h / 53m 9h / 53m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

QuickView: Detecting cancer one drop of blood at a time

VolitionRx - Snaring sepsis, with early NETs detection

VolitionRx - Vetting the pet health opportunity

VolitionRX - Unravelling the web of NETs in sepsis

International Public Partnerships - Consistently and responsibly delivering

Portobello SpA - Focus back on the operations

Intralot - Focus on business development in FY24

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe